The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to provide a significant substantial loss in body weight and improve metabolic markers, par